Natera says NCCN adds Signatera ctDNA-MRD testing to bladder cancer treatment guidelines

Natera, Inc.

Natera, Inc.

NTRA

0.00
  • Natera flagged an NCCN bladder cancer guideline update that adds ctDNA-based MRD testing to post-cystectomy treatment decision-making in MIBC.
  • Evidence was generated in the Phase 3 IMvigor011 trial, with results already reflected in a Category 1, test-guided adjuvant atezolizumab recommendation.
  • The change positions Signatera’s tumor-informed MRD approach as a clinically actionable tool to identify higher-risk patients for adjuvant immunotherapy.
  • Natera noted the FDA cleared Signatera CDx in May 2026 as a companion diagnostic for selecting ctDNA-MRD-positive MIBC patients for adjuvant immunotherapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260623843077) on June 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.